Scarica l'app Stockscreener
1.31
5.76%
-0.08
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Geode Capital Management LLC Lowers Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Barclays PLC Increases Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
State Street Corp Has $5.15 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Fmr LLC Acquires 32,332 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics: We're About To Find Out If Their ADC Platform Is More Tolerable - Seeking Alpha
BNP Paribas Financial Markets Sells 98,881 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Atom Investors LP - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St
Acuta Capital Partners LLC Sells 463,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics (FRA:0M4) Future 3-5Y EPS without NRI Growth Rate : 17.91 (As of Nov. 24, 2024) - GuruFocus.com
Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - MSN
This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN
Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics Q3 2024 Earnings Preview - MSN
Mersana Therapeutics (FRA:0M4) Cash Flow from Operations : €-87.38 Mil (TTM As of Sep. 2024) - GuruFocus.com
16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat
FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat
Mersana Therapeutics transferred with Buy rating at Citi - MSN
Mersana Therapeutics (FRA:0M4) Median PS Value : €0.00 (As of Nov. 24, 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com Nigeria
MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.02 Mil (As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials - Investing.com
Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey
Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
FANG Index (FGU25) Quote - The Globe and Mail
3.26%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):